Drug intelligence / Profile preview

anti-IL-1R antibody

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

An **anti-IL-1R antibody** is a class of monoclonal antibodies designed to target and neutralize the interleukin-1 receptor type 1 (IL-1R1). By binding to IL-1R1, these antibodies competitively inhibit the binding of the pro-inflammatory cytokines interleukin-1 alpha (IL-1alpha) and interleukin-1 beta (IL-1beta), thereby blocking downstream signaling pathways such as NF-kappaB and MAPK. This blockade suppresses the inflammatory cascade, making anti-IL-1R antibodies valuable therapeutic candidates for various inflammatory, autoimmune, and oncological conditions where IL-1 signaling is dysregulated.

Other names: anti-IL-1R monoclonal antibodyanti-IL1R monoclonal antibodyanti-IL 1R monoclonal antibodyanti-IL-1R1 antibodyanti-IL1R1 antibodyanti-IL 1R1 antibodyanti-IL-1R1 monoclonal antibodyanti-IL1R1 monoclonal antibodyanti-IL 1R1 monoclonal antibodyanti-interleukin-1 receptor 1 antibodyanti-interleukin1 receptor 1 antibodyanti-interleukin 1 receptor 1 antibodyanti-interleukin-1 receptor antibodyanti-interleukin1 receptor antibodyanti-interleukin 1 receptor antibodyanti-interleukin-1 receptor type 1 antibodyanti-interleukin1 receptor type 1 antibodyanti-interleukin 1 receptor type 1 antibody

Targets

IL-1R (Interleukin-1 receptor type 1 (IL-1R1))

Beyond the preview

Go deeper on anti-IL-1R antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-IL-1R antibody.

Explore the full profile